文献速递前列腺癌

ProstaTrend:一种用于侵袭性前列腺癌的多变量预后RNA表达评分

ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer.
PubMed 文献 · Eur Urol · 2020-07-04

本研究基于233例根治性前列腺切除术组织标本(新鲜冷冻、FFPE及活检),通过转录组测序和定制表达微阵列开发了一个约含1400个基因的RNA表达评分ProstaTrend。该评分在训练队列中与疾病死亡时间(DoD)显著相关(p=2e-09),并在TCGA独立队列中与生化复发(BCR)显著相关(p=3e-06)。多变量Cox回归调整后预后影响仍持续存在。

要点

  • ProstaTrend是一个基于转录组的评分,可预测根治性前列腺切除术后患者的疾病死亡时间和生化复发。
  • 评分包含约1400个基因,通过加权中位数方法组合。
  • 在多变量分析调整Gleason分级组≥3和切除状态后,预后影响仍显著。

核心结论

  • ProstaTrend是一个基于转录组的评分,可预测接受根治性前列腺切除术的前列腺癌患者的疾病死亡时间和生化复发。

研究设计与样本

  • 评估了233例前列腺癌患者的组织标本,包括新鲜冷冻根治性前列腺切除术标本、FFPE根治性前列腺切除术标本和活检标本,通过转录组范围下一代测序和定制表达微阵列进行分析。
  • 应用Cox比例风险模型于不同平台和标本类型的队列,并通过固定效应荟萃分析组合证据以识别预测疾病死亡时间的基因。
  • 基因通过加权中位数方法组合成预后评分ProstaTrend,并在TCGA独立队列中转移用于预测根治性前列腺切除术后生化复发。

主要发现

  • ProstaTrend包含约1400个基因,在训练队列中与疾病死亡时间显著相关(留一交叉验证,Cox回归:p=2e-09)。
  • 在TCGA验证队列中与生化复发显著相关(Cox回归:p=3e-06)。
  • 多变量Cox回归分析调整Gleason分级组≥3和切除状态后,预后影响持续存在(p=0.001;疾病死亡时间,训练队列)。
  • 调整Gleason分级组≥3、病理分期≥T3和切除状态后,预后影响持续存在(p=0.037;生化复发,验证队列)。

临床怎么用

  • ProstaTrend可提供根治性前列腺切除术后患者的分子风险分层,辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PCa) is the most prevalent solid cancer among men in Western Countries. The clinical behavior of localized PCa is highly variable. Some cancers are aggressive leading to death, while others can even be monitored safely. Hence, there is a high clinical need for precise biomarkers for identification of aggressive disease in addition to established clinical parameters. OBJECTIVE: To develop an RNA expression-based score for the prediction of PCa prognosis that facilitates clinical decision making. DESIGN, SETTING, AND PARTICIPANTS: We assessed 233 tissue specimens of PCa patients with long-term follow-up data from fresh-frozen radical prostatectomies (RPs), from formalin-fixed and paraffin-embedded RP specimens and biopsies by transcriptome-wide next-generation sequencing and customized expression microarrays. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We applied Cox proportional hazard models to the cohorts from different platforms and specimen types. Evidence from these models was combined by fixed-effect meta-analysis to identify genes predictive of the time to death of disease (DoD). Genes were combined by a weighted median approach into a prognostic score called ProstaTrend and transferred for the prediction of biochemical recurrence (BCR) after RP in an independent cohort of The Cancer Genome Atlas (TCGA). RESULTS AND LIMITATIONS: ProstaTrend comprising ∼1400 genes was significantly associated with DoD in the training cohort of PCa patients treated by RP (leave-one-out cross-validation, Cox regression: p=2e-09) and with BCR in the TCGA validation cohort (Cox regression: p=3e-06). The prognostic impact persisted after multivariable Cox regression analysis adjusting for Gleason grading group (GG) ≥3 and resection status (p=0.001; DoD, training cohort) and for GG≥3, pathological stage ≥T3, and resection state (p=0.037; BCR, validation cohort). CONCLUSIONS: ProstaTrend is a transcriptome-based score that predicts DoD and BCR in cohorts of PCa patients treated with RP. PATIENT SUMMARY: ProstaTrend provides molecular patient risk stratification after radical prostatectomy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kreuz M, Otto DJ, Fuessel S, et al. ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. Eur Urol. 2020. PMID: 32631745. doi:10.1016/j.eururo.2020.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。